State Street Corp Krystal Biotech, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, State Street Corp holds 1,452,811 shares of KRYS stock, worth $258 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,452,811

Previous 1,332,875 9.0%

Holding current value

$258 Million

Previous $245 Million 7.94%

% of portfolio

0.01%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $21 Million - $25.6 Million	119,936 Added 9.0%	1,452,811 $264 Million
Q2 2024 Aug 14, 2024	BUY	$153.12 - $183.64 $59.5 Million - $71.3 Million	388,328 Added 41.11%	1,332,875 $245 Million
Q1 2024 May 15, 2024	SELL	$108.01 - $179.35 $31.6 Million - $52.5 Million	-292,950 Reduced 23.67%	944,547 $168 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $19.7 Million - $26.4 Million	205,670 Added 19.93%	1,237,497 $154 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $13.9 Million - $16.7 Million	128,136 Added 14.18%	1,031,827 $120 Million
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $9.63 Million - $16 Million	-122,704 Reduced 11.95%	903,691 $106 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $911,245 - $1.06 Million	-12,588 Reduced 1.21%	1,026,395 $82.2 Million
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $2.83 Million - $3.58 Million	44,839 Added 4.51%	1,038,983 $82.3 Million
Q3 2022 Nov 15, 2022	SELL	$64.85 - $82.4 $2.72 Million - $3.45 Million	-41,897 Reduced 4.04%	994,144 $69.3 Million
Q2 2022 Aug 15, 2022	SELL	$48.93 - $73.47 $1.6 Million - $2.4 Million	-32,615 Reduced 3.05%	1,036,041 $68 Million
Q1 2022 May 16, 2022	BUY	$51.99 - $72.11 $19.1 Million - $26.5 Million	366,855 Added 52.27%	1,068,656 $71.1 Million
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $1.4 Million - $3.11 Million	-35,252 Reduced 4.78%	701,801 $49.1 Million
Q3 2021 Nov 15, 2021	BUY	$52.01 - $71.77 $1.25 Million - $1.73 Million	24,056 Added 3.37%	737,053 $38.5 Million
Q2 2021 Aug 16, 2021	BUY	$62.14 - $81.82 $3.36 Million - $4.42 Million	54,039 Added 8.2%	712,997 $48.5 Million
Q1 2021 May 17, 2021	BUY	$59.42 - $85.46 $5.87 Million - $8.44 Million	98,708 Added 17.62%	658,958 $50.8 Million
Q4 2020 Feb 16, 2021	SELL	$40.64 - $61.38 $1.3 Million - $1.97 Million	-32,086 Reduced 5.42%	560,250 $33.6 Million
Q3 2020 Nov 10, 2020	SELL	$37.76 - $48.49 $3.87 Million - $4.97 Million	-102,489 Reduced 14.75%	592,336 $25.5 Million
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $8.42 Million - $13.6 Million	227,432 Added 48.66%	694,825 $28.8 Million
Q1 2020 May 11, 2020	BUY	$35.02 - $65.64 $16.4 Million - $30.7 Million	467,393 New	467,393 $20.2 Million

Others Institutions Holding KRYS

# of Institutions

310

Shares Held

24.4M

Call Options Held

483K

Put Options Held

364K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.55B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Krystal Biotech, Inc. Transaction History